Drug Combination Details
| General Information of the Combination (ID: C01714) | |||||
|---|---|---|---|---|---|
| Name | Fucoxanthin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Cervical cancer
[ICD-11: 2C77]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HeLa | CVCL_0030 | Endocervical adenocarcinoma | Homo sapiens | ||
| SiHa | CVCL_0032 | Cervical squamous cell carcinoma | Homo sapiens | |||
| Ca Ski | CVCL_1100 | Cervical squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | Five-week-old nude BALB/c mice were used for subcutaneous implantation of human cervical tumor cells HeLa (2*106 per site). | |||||
| Experimental
Result(s) |
The combination of TRAIL with fucoxanthin showed synergistically inhibitory effects on cervical cancer cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Sensitization of TRAIL-resistant cervical cancer cells through combination of TRAIL and fucoxanthin treatments. Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5594-5601. | |||
